Journal of Vaccines & Vaccination

Identification of immunotherapeutic epitope of E5 Protein of Human Papillomavirus-16

5^th Asia Pacific Global Summit and Expo on Vaccines & Vaccination

July 27-29, 2015 Brisbane, Australia

Anoop Kumar1,3, Inderjit Singh Yadav2, Showket Hussain1, Bhudev C. Das3, Mausumi Bharadwaj1

Posters-Accepted Abstracts: J Vaccines Vaccin

Abstract:

In India, cervical cancer is the most frequent gynecological cancer and approximately 432.20 million Indian women above 15 years of age are at risk of developing cervical cancer. India contributes about 1/3rd of the global cervical cancer deaths, with estimates of 132,000 new cases diagnosed and 74,000 deaths annually. The persistent infection with high risk-HPV (HR-HPV) is the major cause of cervical cancer, worldwide. Two developed prophylactic HPV vaccine (Gardasil and Cerverix) provide protection against HPV induced cervical malignancy. However, vaccines having therapeutic values are of utmost priority. Till date, most of HPV therapeutic vaccines are focused on two major HPV oncoproteins (E6/E7). HPV-E5 which acts by altering the activity of cellular proteins, mainly growth factor pathways emerges as a new therapeutic target. In the present study, we predicted the epitopes of HPV16-E5 to identify the candidate B-cell and T-cell epitopes, which can be used for HPV immunotherapy. We identified that epitope SAFRCFIVYIIFVY is the most potent peptide for HLA-A*11:01 having percentile value of 0.5 and immunogenicity score of 0.69558. For MHC-II, the epitopes IPLFLIHTHARFLIT for HLA-DRB1*14:01 alleles have the lowest IC50 value (18.13nM). The identification of structural feature and immunogenic epitopes provides the best information for development of drugs or vaccine. In conclusion, as the expression of E5 protein was detected in the early phase of the HPV infection, there may be an opportunity to target HPV-E5 that would help in the prevention and progression of the precancerous lesion to invasive carcinomas.